Senseonics (NYSE:SENS) shares took a hit today on second-quarter results that missed the consensus earnings forecast.
The Germantown, Md.-based diabetes management technology developer posted losses of –$180.3 million on sales of $3.3 million for the three months ended June 30, 2021, seeing its bottom line plummet from losses of just –$7.5 million this time last year. Revenues were more than 11 times of the tally registered in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.